Ra Pharmaceuticals, Inc.
Industry
- Biotechnology
- Large Molecule
- Drug Discovery Technologies
- Antisense, Oligonucleotides
- Pharmaceuticals
Other Names/Subsidiaries
- UCB S.A.
Latest on Ra Pharmaceuticals, Inc.
Mariana Oncology Inc. CEO Simon Read believes that one of the reasons his company was able to raise the $175m series B venture capital round announced on 7 September was its differentiated approach t
UCB S.A. ’s complement component 5 (C5) inhibitor peptide zilucoplan hit the primary endpoint and two secondary endpoints in a Phase III study in generalized myasthenia gravis (gMG), the firm announce
UCB S.A. has moved closer to becoming a major player in the generalized myasthenia gravis (gMG) space with rozanolixizumab, one of the Belgian group's two late-stage candidates for the rare autoimmun
Several PCSK9 inhibitors have demonstrated strong efficacy when it comes to reducing LDL-cholesterol, but none have had the promise of being available orally – until now Merck & Co., Inc. announced